# A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)

Study · id `cardio:ct-nct01611883` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01611883](<https://clinicaltrials.gov/study/NCT01611883>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01611883

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

## Technical summary

Registry record NCT01611883. Randomized; double masking; primary purpose treatment. Start 2012-07-02 (actual); primary completion 2014-01-16 (actual). Results posted on 2014-12-17.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 152 participants (enrolled count; ClinicalTrials.gov record NCT01611883, source copy `cardio:ctgov-nct01611883-2024-05-24`, retrieved 2026-10-31)
- Started: 2012-07-02 (actual) (ClinicalTrials.gov record NCT01611883, source copy `cardio:ctgov-nct01611883-2024-05-24`, retrieved 2026-10-31)
- Primary completion: 2014-01-16 (actual) (ClinicalTrials.gov record NCT01611883, source copy `cardio:ctgov-nct01611883-2024-05-24`, retrieved 2026-10-31)
- Completion: 2014-01-16 (actual) (ClinicalTrials.gov record NCT01611883, source copy `cardio:ctgov-nct01611883-2024-05-24`, retrieved 2026-10-31)
- Results first posted: 2014-12-17 (ClinicalTrials.gov record NCT01611883, source copy `cardio:ctgov-nct01611883-2024-05-24`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01611883-2024-05-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)
- Condition: Hypercholesterolemia
- Intervention (Drug): Ezetimibe
- Intervention (Drug): Placebo
- Lead sponsor: Organon and Co
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry lists this organization as the lead sponsor: Organon and Co (`cardio:org-organon-and-co`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia (`cardio:pubmed-25929253`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1f9c57c746da20be2403868e0ef90f01ae20ff8b11b10d3f02c4189fe1aed8f4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
